Successful Treatment of Myasthenia Gravis Following PD-1/CTLA-4 Combination Checkpoint Blockade in a Patient With Metastatic Melanoma

Successful Treatment of Myasthenia Gravis Following PD-1/CTLA-4 Combination Checkpoint Blockade in a Patient With Metastatic Melanoma

Currently, the blockade of certain immune checkpoints such as the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death-1 (PD-1) using checkpoint inhibitors is standard of care in patients with metastatic melanoma, especially with BRAF wild-type. However, several checkpoint...

Full description

Bibliographic Details
Main Authors: Jan-Michael Werner, Viola Schweinsberg, Michael Schroeter, Boris von Reutern, Michael P. Malter, Max Schlaak, Gereon R. Fink, Cornelia Mauch, Norbert Galldiks
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-02-01
Series:Frontiers in Oncology
Subjects:
nivolumab
ipilimumab
myasthenic crisis
immunotherapy
checkpoint inhibitor
neuro-oncology
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2019.00084/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2019.00084/full

Similar Items